Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients With Metastatic Castration-Resistant Prostate Cancer.

NCT03774056 is registered in ClinicalTrials.gov with Hinova Pharmaceuticals Inc. as lead sponsor.

NCT NCT03774056
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03774056 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients With Metastatic Castration-Resistant Prostate Cancer.
Lead sponsor
Hinova Pharmaceuticals Inc.
Phase
Phase 1
Overall status
Completed
Start date
February 10, 2017
Completion date
August 28, 2019
Enrollment
43 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration resistant prostate cancer